Abstract 2266: Characterization of activins and their related molecules in colorectal cancer according to clinical stage, tumor sidedness and the expression of PI3K/mTOR proteins

In colorectal cancer, CD133+ cells from fresh biopsies proved to be more tumorigenic than their CD133– counterparts. Nevertheless, the function of CD133 protein in tumorigenic cells seems only marginal. Moreover, CD133 expression alone is insufficient to isolate true cancer stem cells, since only 1 out of 262 CD133+ cells actually displays stem-cell capacity. Thus, new markers for colorectal cancer stem cells are needed. Here, we show the extensive characterization of CD133+ cells in 5 different colon carcinoma continuous cell lines (HT29, HCT116, Caco2, GEO and LS174T), each representing a different maturation level of colorectal cancer cells. Markers associated with stemness, tumorigenesis and metastatic potential were selected. We identified 6 molecules consistently present on CD133+ cells: CD9, CD29, CD49b, CD59, CD151, and CD326. By contrast, CD24, CD26, CD54, CD66c, CD81, CD90, CD99, CD112, CD164, CD166, and CD200 showed a discontinuous behavior, which led us to identify cell type-specific surface antigen mosaics. Finally, some antigens, e.g. CD227, indicated the possibility of classifying the CD133+ cells into 2 subsets likely exhibiting specific features. This study reports, for the first time, an extended characterization of the CD133+ cells in colon carcinoma cell lines and provides a “dictionary” of antigens to be used in colorectal cancer research.

Download Full-text

Scope of Artificial Intelligence in Screening and Diagnosis of Colorectal Cancer

Journal of Clinical Medicine ◽

10.3390/jcm9103313 ◽

2020 ◽

Vol 9 (10) ◽

pp. 3313 ◽

Cited By ~ 2

Author(s):

Hemant Goyal ◽

Rupinder Mann ◽

Zainab Gandhi ◽

Abhilash Perisetti ◽

Aman Ali ◽

...

Keyword(s):

Artificial Intelligence ◽

Colorectal Cancer ◽

Cancer Screening ◽

Colorectal Cancer Screening ◽

Narrow Band Imaging ◽

Screening Methods ◽

Polyp Detection ◽

Mortality And Morbidity ◽

Magnifying Chromoendoscopy

Globally, colorectal cancer is the third most diagnosed malignancy. It causes significant mortality and morbidity, which can be reduced by early diagnosis with an effective screening test. Integrating artificial intelligence (AI) and computer-aided detection (CAD) with screening methods has shown promising colorectal cancer screening results. AI could provide a “second look” for endoscopists to decrease the rate of missed polyps during a colonoscopy. It can also improve detection and characterization of polyps by integration with colonoscopy and various advanced endoscopic modalities such as magnifying narrow-band imaging, endocytoscopy, confocal endomicroscopy, laser-induced fluorescence spectroscopy, and magnifying chromoendoscopy. This descriptive review discusses various AI and CAD applications in colorectal cancer screening, polyp detection, and characterization.

Download Full-text

The characterization of exosome from blood plasma of patients with colorectal cancer

10.1063/1.4960289 ◽

2016 ◽

Cited By ~ 7

Author(s):

N. V. Yunusova ◽

S. N. Tamkovich ◽

M. N. Stakheeva ◽

S. G. Afanas’ev ◽

A. Y. Frolova ◽

...

Keyword(s):

Colorectal Cancer ◽

Blood Plasma

Download Full-text

In-depth Characterization of the Secretome of Colorectal Cancer Metastatic Cells Identifies Key Proteins in Cell Adhesion, Migration, and Invasion

Molecular & Cellular Proteomics ◽

10.1074/mcp.m112.022848 ◽

2013 ◽

Vol 12 (6) ◽

pp. 1602-1620 ◽

Cited By ~ 74

Author(s):

Rodrigo Barderas ◽

Marta Mendes ◽

Sofia Torres ◽

Rubén A. Bartolomé ◽

María López-Lucendo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cell Adhesion ◽

Migration And Invasion ◽

Metastatic Cells

Download Full-text

Characterization of Aes nuclear foci in colorectal cancer cells

The Journal of Biochemistry ◽

10.1093/jb/mvv077 ◽

2015 ◽

Vol 159 (1) ◽

pp. 133-140 ◽

Cited By ~ 1

Author(s):

Yoshiro Itatani ◽

Masahiro Sonoshita ◽

Fumihiko Kakizaki ◽

Katsuya Okawa ◽

Stefano Stifani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Cells ◽

Colorectal Cancer Cells ◽

Nuclear Foci

Download Full-text

Genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer

Cell Host & Microbe ◽

10.1016/j.chom.2021.08.013 ◽

2021 ◽

Author(s):

Melissa C. Kordahi ◽

Ian B. Stanaway ◽

Marion Avril ◽

Denise Chac ◽

Marie-Pierre Blanc ◽

...

Keyword(s):

Colorectal Cancer ◽

Early Stage ◽

Functional Characterization

Download Full-text

Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS

Journal of Proteomics ◽

10.1016/j.jprot.2018.04.026 ◽

2018 ◽

Vol 181 ◽

pp. 225-237 ◽

Cited By ~ 11

Author(s):

Si Liu ◽

Liming Cheng ◽

Yang Fu ◽

Bi-Feng Liu ◽

Xin Liu

Keyword(s):

Colorectal Cancer ◽

Cancer Progression ◽

Maldi Tof Ms ◽

Maldi Tof ◽

Colorectal Cancer Progression ◽

Tof Ms

Download Full-text

Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.3608 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 3608-3608

Author(s):

Hiroki Yukami ◽

Yoshiaki Nakamura ◽

Jun Watanabe ◽

Masahito Kotaka ◽

Kentaro Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Dna Analysis ◽

Residual Disease ◽

Clinical Stage ◽

Circulating Tumor Dna ◽

Patient Specific ◽

Detection Rates ◽

Initial Report ◽

Post Surgery ◽

Tumor Dna

3608 Background: Circulating tumor DNA (ctDNA) analysis can be used to predict the risk of recurrence by detecting molecular residual disease (MRD) in patients with colorectal cancer (CRC). We are conducting a prospective observational study to monitor MRD status in patients with clinical stage II–IV or relapsed CRC amenable to radical surgical resection (GALAXY study), as part of the CIRCULATE-Japan, a nationwide ctDNA-guided precision adjuvant therapy project. Methods: Analysis of ctDNA is being performed at pre- and post-surgery timepoints and will continue periodically for up to 2 years using Signatera, a personalized, tumor-informed ctDNA assay that is designed to track 16 patient-specific somatic variants based on whole-exome sequencing of tumor tissue. The association of peri-operative ctDNA status with clinicopathological characteristics was investigated. Results: As of January 13, 2021, 941 patients have been enrolled in the GALAXY study, of which 400 patients had their pre-operative ctDNA status evaluated. Of the 400 patients, baseline ctDNA was detected in 92% (367/400) of the patients: consisting of 35 patients with pathological stage (pStage) I, 135 with pStage II, 152 with pStage III, and 78 with pStage IV or relapsed disease (pStage IV/R). Patient-specific Signatera assays targeting 16 variants were designed for 100% of the patients. Out of the 6400 designed variants 99.3% passed quality control in the plasma analysis and produced the final results. Among 4425 genes selected for 400 patients, 3330 genes were selected for only one patient, while TP53 was the most commonly selected in 113 patients (28%). Median ctDNA levels, measured in mean tumor molecules per mL of plasma and ctDNA detection rate, stratified by stage are presented in table. Positive ctDNA status post-surgery was significantly associated with advanced pStage, pT and pN, and lymphovascular invasion. Of the 13 patients with recurrence, 10 were detected with a positive ctDNA at 4-weeks post-surgery, before confirmation of recurrence by the radiological imaging. Conclusions: Preoperative ctDNA detection rates were observed to be in >90% in patients with pStage II–III by personalized ctDNA assay based on unique somatic variants, specific to each patient. ctDNA- based MRD detected post-surgery (4W) was significantly associated with certain known clinicopathological factors for recurrence with ctDNA positivity associated with a very short-term of recurrence. Clinical trial information: 000039205. [Table: see text]

Download Full-text